| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.5 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.02 | 0.5 |
| mRNA | necrostatin-1 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.017 | 0.5 |
| mRNA | AZD-2281 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | AM-580 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | navitoclax:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |